Mass Tort brief
Catheter Verdicts and Preemption Shifts Reset Injury Dockets
A $40M catheter award and infant formula defense verdicts reset trial leverage across major federal product liability dockets.
Mass Tort
A $40M jury award confirmed Bard PowerPorts carry design defects — handing 3,700 plaintiffs decisive leverage in global settlement talks.
BackgroundImplantable chemotherapy ports sit under the skin to channel medication directly into central veins. Patients claim barium sulfate added to make the tubing visible on X-rays degraded the plastic, leading to fatal catheter breakages.
- The federal jury found Bard liable for negligent design and failure to warn after a migrated catheter fragment required emergency open-heart surgery.
- The outcome marks a critical turnaround from an earlier defense verdict on infection claims, establishing real settlement value for thousands of pending fracture lawsuits.
- A third federal bellwether examining catheter thrombosis and bloodstream infections begins October 13, testing whether Bard faces liability across multiple distinct injury mechanisms.
Mass Tort
With lead counsel ousted and medical experts withdrawn, 69,200 talc suits face mass culling — leaving plaintiffs with shrinking leverage against J&J.
BackgroundTens of thousands of consumers sued Johnson & Johnson, alleging asbestos in cosmetic talcum powder caused ovarian cancer and mesothelioma. J&J previously attempted to resolve the liabilities through two controversial subsidiary bankruptcies that federal appellate courts dismissed.
- The show-cause order targets cohorts where plaintiffs' attorneys withdrew specific-causation medical expert reports rather than defend their methodologies under cross-examination.
- Plaintiffs' steering committee lost its lead trial counsel after the court disqualified Beasley Allen over ethical violations involving former defense attorneys.
- J&J is using the evidentiary void to push remaining plaintiffs toward a discounted out-of-court settlement before surviving claims reach individual state juries.
Mass Tort
Pruning the test pool to five cases accelerates 12,000 relaxer claims toward trial — making November's Daubert hearing the make-or-break hurdle for plaintiffs.
BackgroundMultidistrict litigation centralizes thousands of civil claims before one federal judge to coordinate discovery and conduct representative bellwether trials. Tens of thousands of women allege endocrine-disrupting chemicals in cosmetic hair straighteners caused uterine and ovarian cancers.
- Case Management Order 24 established end-of-September deadlines for written interrogatories while extending corporate witness depositions through July 2027.
- Mid-November Daubert hearings will decide whether plaintiffs' scientific expert evidence linking chemical straighteners to reproductive malignancies meets federal admissibility standards.
- Defendants including L'Oréal USA and Strength of Nature are preparing individual defense strategies for the five designated test trials set for early 2027.
Mass Tort
Mead Johnson's defense verdict broke plaintiffs' winning streak — restoring manufacturer leverage against hundreds of claims that cow's milk formula sickened premature infants.
BackgroundNecrotizing enterocolitis is a life-threatening intestinal inflammation that strikes premature infants in neonatal intensive care units. Bereaved parents argue infant formula companies knew bovine milk dramatically increased infection risks compared to human donor milk yet failed to notify physicians.
- Jurors rejected claims of negligent design defect and failure to warn after five hours of deliberation following a two-week federal trial.
- The complete defense win halts plaintiff momentum after multi-million-dollar state court verdicts in Illinois and Missouri rattled formula manufacturers.
- Hundreds of formula claims remain pending in federal multidistrict proceedings as plaintiffs reevaluate their expert testimony ahead of the next scheduled bellwether.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
